Home›Trial›NCT05180799
🔬NCT05180799Phase 1Phase 2ACTIVE NOT RECRUITING

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Study Summary

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors

Conditions
NSCLCMelanoma
Interventions / Drugs
BA3071NivolumabPembrolizumabPemetrexed (Alimta)
View on ClinicalTrials.gov ↗
Sponsor
BCAB
BioAtla Inc
Oncology
D38/100
Study Details
Enrollment320 participants
Primary Completion—
Lead SponsorBioAtla, Inc.
Data Retrieved2026-04-11 04:07:01.755239+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.